Interestingly, HDAC inhibitors developed for cancer therapy do exert their activity in part via increasing the expression of BIM38,39 suggesting a potential molecular mechanism of how NCOR1 might repress BIM transcription. This evidence concerns the gene BCL2L11 and cancer.